Goldman Sachs analyst Davin Thillainathan initiated coverage of Fisher & Paykel Healthcare with a Buy rating and A$42.70 price target The firm sees an acceleration of revenue in the company’s hospital segment.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FSPKF: